Infectious Diseases and HIV Medicine
Publications
Enhancing resistance to cephalosporins in class C beta-lactamases
Enhancing resistance to cephalosporins in class C beta-lactamases
"Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2"
Biochemistry. 2010 Feb 9
Endimiani A, Doi Y, Bethel CR, Taracila M, Adams-Haduch JM, O'Keefe A, Hujer AM, Paterson DL, Skalweit MJ, Page MG, Drawz SM, Bonomo RA.
Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland
The biochemical properties of CMY-32, a class C enzyme possessing a single-amino acid substitution in the Omega loop (Gly214Glu), were compared to those of the parent enzyme, CMY-2, a widespread class C beta-lactamase. In parallel with our microbiological characterization, the Gly214Glu substitution in CMY-32 reduced catalytic efficiency (k(cat)/K(m)) by 50-70% against "good" substrates (i.e., cephalothin) while increasing k(cat)/K(m) against "poor" substrates (i.e., cefotaxime). Additionally, CMY-32 was more susceptible to inactivation by sulfone beta-lactamase inhibitors (i.e., sulbactam and tazobactam) than CMY-2. Timed electrospray ionization mass spectrometry (ESI-MS) analysis of the reaction of CMY-2 and CMY-32 with different substrates and inhibitors suggested that both beta-lactamases formed similar intermediates during catalysis and inactivation. We next showed that the carbapenems (imipenem, meropenem, and doripenem) form long-lived acyl-enzyme intermediates and present evidence that there is beta-lactamase-catalyzed elimination of the C(6) hydroxyethyl substituent. Furthermore, we discovered that the monobactam aztreonam and BAL29880, a new beta-lactamase inhibitor of the monobactam class, inactivate CMY-2 and CMY-32 by forming an acyl-enzyme intermediate that undergoes elimination of SO(3)(2-). Molecular modeling and dynamics simulations suggest that the Omega loop is more constrained in CMY-32 than CMY-2. Our model also proposes that Gln120 adopts a novel conformation in the active site while new interactions form between Glu214 and Tyr221, thus explaining the increased level of cefotaxime hydrolysis. When it is docked in the active site, we observe that BAL29880 exploits contacts with highly conserved residues Lys67 and Asn152 in CMY-2 and CMY-32. These findings highlight (i) the impact of single-amino acid substitutions on protein evolution in clinically important AmpC enzymes and (ii) the novel insights into the mechanisms by which carbapenems and monobactams interact with CMY-2 and CMY-32 beta-lactamases.

- Division Chief Message
- News
- Publications
- Penicillin sulfone inhibitors of class D beta-lactamases
- In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates.
- Evaluation of an alcohol-based power sanitizing system
- Saline Nebulization before Gastric Lavage in the Diagnosis of Pulmonary Tuberculosis in Children and Adolescents
- Preserved MHC class II antigen processing in monocytes from HIV-infected individuals
- Acinetobacter baumannii-associated skin and soft tissue infections
- Streptococcus anginosus Pyomyositis in a 50-Year-Old Man with Acquired Immunodeficiency Syndrome
- Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes
- Influenza-Induced Production of Interferon-Alpha is Defective in Geriatric Individuals
- Enhancing resistance to cephalosporins in class C beta-lactamases
- Three decades of beta-lactamase inhibitors
- In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates
- Persistence of skin contamination & environmental shedding of Clostridium difficile
- Comparative description of haplotype structure and genetic diversity of MDR1
- Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design
- Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase
- Increased tissue factor expression on circulating monocytes in chronic HIV infection
- Faculty
- Research
- The Fight Against TB
- Patient Care
- Fellowship Program
- Contacts
